Mark Bresnik

Liposomal Amphotericin B as Initial Therapy for Invasive Mold Infection: A Randomized Trial Comparing a High-Loading Dose Regimen with Standard Dosing (AmBiLoad Trial)

Oliver A. Cornely, Johan Maertens, Mark Bresnik et al. · Clinical Infectious Diseases · 2007 · 744 citations · Full text

Medicine, Infectious Diseases, Pharmacology +17

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial

B.M. Assael, Tacjana Pressler, Diana Bilton et al. · Journal of Cystic Fibrosis · 2012 · 136 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia

Oliver A. Cornely, Thibaut Leguay, Johan Maertens et al. · Journal of Antimicrobial Chemotherapy · 2017 · 88 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study

Harm A.W.M. Tiddens, K. De Boeck, John Clancy et al. · Journal of Cystic Fibrosis · 2014 · 60 citations

Medicine, Pediatrics, Pharmacotherapy +16

Efficacy outcomes in a randomised trial of liposomal amphotericin B based on revised EORTC/MSG 2008 definitions of invasive mould disease

Oliver A. Cornely, Johan Maertens, Mark Bresnik et al. · Mycoses · 2010 · 58 citations · Full text

Life Sciences, Oncology, Chemotherapy +14